SecBot SecBot

CUE

Cue Biopharma, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001645460 Biotech & Drug Discovery
$18.45 −0.21 (−1.13%)
Oct 26 4:00 PM ET · prev $18.66
Market cap
$137.2M
Micro cap
Consensus
Buy
83% Buy or better · 6 analysts
Median target
$83.00
+350% · range $66.00–115.00
Next earnings
Nov 12
in 17 days · EPS est. −$2.24
1 year
−20.1%
from $23.10 · Oct 27
30 days
−32.8%
from $27.45
52-week range
$5.31–37.84
−51% from high · low Apr 6
Avg volume 20D
186.4K
shares / day
Short interest
702.2K
≈9.7% of shares · +111.4%
Days to cover
1.1
at average volume
Insider net
−$1.4M
1 buyer · 3 sellers · 12 mo
Filing reports
19
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 3 bearish · 2 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 8/9 ·Next Earnings date, Nov 12, 2026
Strongest BULLISH Cue Biopharma announced positive topline results from a Phase 2 clinical trial of CUE-221 in chronic…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $1000.0K. 3 insiders sold $2.4M.

  • AnalystsBULLISH

    5 of 6 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$1.910 → −$2.243 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersBUILDING

    Short interest +111.4% to 702.2K shares. 1.1 days to cover, ≈9.7% of shares.

  • TrendDOWNTREND

    29% below its 50-day average.

Who's buying

13F
Top holderSharesValue
ROYAL BANK OF CANADA2$0.00
DRIEHAUS CAPITAL MANAGEMENT LLC292,144$9.2M
VANGUARD CAPITAL MANAGEMENT LLC161,700$5.1M
BlackRock, Inc.57,807$1.8M
GEODE CAPITAL MANAGEMENT, LLC47,824$1.5M
UBS Group AG26,700$842.7K
CITADEL ADVISORS LLC25,633$809.0K
VANGUARD FIDUCIARY TRUST CO24,476$772.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

6 analysts
Buy 83% rate it Buy or better
Strong Buy2Buy3Hold1Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +350%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 18, 2026B. Riley Securities
INITIATE
INITIATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
CUE Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Sep 20, 2026
FDA
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration…
Aug 24, 2026
Press release
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE)
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Cue Biopharma, Inc. (NASDAQ: CUE) on behalf of…
Aug 18, 2026
Earnings date
CUE Q2 2026 Earnings Scheduled — 2026-08-18
Aug 14, 2026
Earnings
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative…
Aug 10, 2026
Earnings date
CUE Q2 2026 Earnings Scheduled — 2026-08-10

Insider ledger

Form 4
$1000.0K
bought · 1 insider
$2.4M
sold · 3 insiders
DateInsiderTypeValue
Oct 12, 2026
Lin Shao-Lee
Chief Executive Officer
SELL$275.0K
Oct 12, 2026
Lin Shao-Lee
Chief Executive Officer
SELL$30.5K
Oct 12, 2026
Meluzio Michael Vincent
VP, Prin. Accounting Officer
SELL$32.1K
Oct 12, 2026
Ray Sumita
Chief Legal Compliance Officer
SELL$51.7K
Aug 13, 2026
Lin Shao-Lee
Chief Executive Officer
SELL$66.8K
Aug 13, 2026
Lin Shao-Lee
Chief Executive Officer
SELL$147.5K
Aug 13, 2026
Lin Shao-Lee
Chief Executive Officer
SELL$308.4K
Aug 13, 2026
Meluzio Michael Vincent
VP, Prin. Accounting Officer
EXERCISE13,647 sh

Earnings setup

Estimates
Nov 12
reports in 17 days
−$2.24
EPS estimate, this quarter
−17%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$2.24-$4.04–-$1.27-58.0%$1.0M
Next Q-$1.76-$2.83–-$0.98-20.3%$1.0M
Current FY-$25.01-$32.12–-$18.63-16.6%$15.6M
Next FY-$7.44-$8.67–-$5.17-9.0%$8.7M

Short side

FINRA· Sep 30, 2026
702,198
shares short
+111.4%
vs prior settlement
1.1
days to cover
≈9.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
CEO Lin Shao-Lee and VP Meluzio Michael Vincent sold a combined $307K in open-market sales on October 12, 2026. The…
CLUSTER — Impact 4/10
Oct 13, 2026 SEC
Sumita Ray, Corporate Secretary of Cue Biopharma, filed a Form 144 notice to sell 1,844 shares of common stock…
144 — Impact 2/10
Oct 12, 2026 Insider
Lin Shao-Lee sold 10,000 shares
Chief Executive Officer @ $27.50 ($275.0K)
Oct 12, 2026 Insider
Lin Shao-Lee sold 1,087 shares
Chief Executive Officer @ $28.05 ($30.5K)
Oct 12, 2026 Insider
Meluzio Michael Vincent sold 1,144 shares
VP, Prin. Accounting Officer @ $28.05 ($32.1K)
Oct 8, 2026 SEC
Mark E. Strome and affiliated entities filed an amended Schedule 13G disclosing aggregate beneficial ownership of…
SC 13G/A — Impact 4/10
Sep 20, 2026 Press
Cue Biopharma announced positive Phase 2 topline results for CUE-221 in chronic spontaneous urticaria (CSU), meeting…
Impact 7/10
Sep 20, 2026 FDA
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Results support potential for differentiated clinical impact for patients suffering from chronic hiv

SecBot reports

19 filings · 6 press releases · 2 bullish · 8 bearish · 9 neutral
All CUE filing & press-release reports (25)